BioCardia Inc (BCDA) USD0.001
BioCardia, Inc. is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.